Related Experiment Video
Updated: Dec 10, 2025
Urinary Tract Infection in a Small Animal Model: Transurethral Catheterization of Male and Female Mice
Published on: December 1, 2017
Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors
Trisha Benjamin1,2, Christine Schumacher1,2
1Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois, USA.
Background:
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are associated with an increased risk of genitourinary infections in patients with type 2 diabetes mellitus (T2DM). It is unknown which factors may predispose patients to an increased risk of developing a genitourinary infection.
Objective:
To evaluate whether hemoglobin A1c levels and other patient-specific factors at initiation of SGLT2 inhibitor therapy were a predictor for increased risk for genitourinary infections.
Methods:
A retrospective, multicenter cohort analysis was conducted using data from ambulatory care clinics within a large medical group. Patients 18 years of age or older with a diagnosis of T2DM who were prescribed a SGLT2 inhibitor between January 1, 2013 and October 31, 2018 and completed therapy for at least seven days were included in the analysis. Firth logistic regression was used to detect differences in baseline characteristics and paired t-tests were used to compare baseline to post-initiation values for prespecified variables for those patients with a confirmed genitourinary infection.
Results:
Of the 739 patients prescribed a SGLT2 inhibitor, 584 were included. Thirty (5.14%) patients experienced a genitourinary infection on SGLT2 inhibitor therapy. Baseline hemoglobin A1c did not confer a significant difference in risk for genitourinary infection (p=0.4239). Estimated glomerular filtration rate (eGFR) was the only variable that significantly differed between those who did and did not develop an infection (p=0.0228). A post hoc analysis reviewing 30 patients initially excluded for a history of genitourinary infection showed 13 (43%) of those patients experienced a genitourinary infection after initiating SGLT2 inhibitor therapy with no difference in risk stratified by baseline hemoglobin A1c level (p=0.9648).
Conclusions:
The incidence of genitourinary infection with SGLT2 inhibitor use was lower than suggested in clinical trials, with lower eGFR and history of genitourinary infection the only identified predictors for increased risk in this population. Genitourinary infection risk should not deter clinicians from recommending or prescribing SGLT2 inhibitor therapy.
Insights
Sodium-glucose cotransporter-2 (SGLT2) inhibitors may increase genitourinary infection risk in type 2 diabetes patients. Lower estimated glomerular filtration rate (eGFR) and prior infections are key risk factors, not HbA1c levels.
Area of Science:
- Endocrinology and Metabolism
- Nephrology
- Infectious Diseases
Background:
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors are linked to increased genitourinary infection risk in type 2 diabetes mellitus (T2DM) patients.
- Identifying patient-specific factors predicting genitourinary infection risk during SGLT2 inhibitor therapy is crucial.
Purpose of the Study:
- To determine if baseline hemoglobin A1c (HbA1c) levels and other patient factors predict genitourinary infection risk upon initiating SGLT2 inhibitor therapy.
Main Methods:
- Retrospective, multicenter cohort analysis of T2DM patients prescribed SGLT2 inhibitors.
- Logistic regression and paired t-tests analyzed baseline characteristics and post-initiation outcomes.
- Included patients aged 18+ who received SGLT2 inhibitors for at least seven days.
Main Results:
- Genitourinary infections occurred in 5.14% of 584 included patients.
- Baseline HbA1c did not significantly predict infection risk (p=0.4239).
- Lower estimated glomerular filtration rate (eGFR) was the sole significant predictor (p=0.0228).
- A post hoc analysis of patients with prior genitourinary infections showed similar infection rates without HbA1c correlation.
Conclusions:
- The incidence of genitourinary infections with SGLT2 inhibitors was lower than reported in clinical trials.
- Lower eGFR and a history of genitourinary infections are key predictors of increased risk.
- SGLT2 inhibitor therapy should not be withheld due to genitourinary infection concerns.
Related Concept Videos
01:21Nursing Assessment of the Genitourinary System I: Health History
01:25Urinary Tract Infection II: Pathophysiology
01:26Urine Studies II: Urine Culture and Sensitivity Test
01:26Urinary Tract Infection I: Introduction
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care